Covalon Technologies Ltd. (OTC:CVALF)

Friday, November 21, 2025 | Web News
Yesterday, Covalon Technologies Ltd. (TSXV:COV) (OTC:CVALF) (C$1.90; C$52.5M market cap) announced the payment of a...
Tuesday, October 21, 2025 | Web News
Covalon Technologies Ltd. (TSXV:COV) (OTC:CVALF) (C$2.08; C$57.0M market cap) announced a special dividend declaration:...
Tuesday, May 20, 2025 | Web News
Covalon Technologies Ltd. (TCOV.V) (OTC:CVALF) ($2.64; $72.2M market cap) announced it has retained Origin Merchant Partners...
See All Research...
Sunday, October 27, 2024, 3:22 PM
Positing 100% Short-Term Upside in Med-Tech Company Covalon (CVALF) (COV.V)
See All Articles and Reports...
Sunday, November 23, 2025, 3:29 PM
Tecogen Partnership Update with Vertiv, Another Skull Session with Biorem CEO, Weekly Earnings Highlights [GeoWire Weekly No. 214] | FSI KTEL TGEN BRM.V INX.V COV.V
Sunday, October 26, 2025, 1:24 PM
The Daffy Duck Investing Playbook: Ugly Ducklings Can Be Pretty on the Inside [GeoWire Weekly No. 210]
Sunday, October 12, 2025, 6:35 PM
Our Current Top Five Ideas October 2025 Open Forum Highlights [GeoWire Weekly No. 208]
See All GeoWire Weekly...
Covalon Technologies Ltd. researches, develops, manufactures, commercializes, and licenses medical technologies and products in the United States, Canada, the United Kingdom, Europe, the Middle East, Asia, Latin America, and internationally. The company has five proprietary platform technologies, including collagen matrix platform that is used to manufacture a family of products to treat chronic and infected wounds, including diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns; antimicrobial silicone adhesive platform that is used for family of pre and post-surgical, and vascular access products that are designed to kill bacteria or yeast that comes into contact with the antimicrobial silicone providing broad-spectrum antimicrobial activity; medical coating platform, a proprietary process that utilizes photo-polymerization to create active grafting sites where new polymer chains are initiated and propagated from the surface of an existing medical device; aquaguard moisture barrier technology, an impermeable moisture barrier that allows the clinician or patient to cover wounds, dressings, and intravenous sites to keep them dry; and covaguard antimicrobial sanitizing technology that incorporates Benzalkonium Chloride into a lipid delivery system to surfaces and skin to kill viruses and bacteria. Its products include wound care dressings; surgical and peri-operative products; infection management products; moisture barriers; and antimicrobial sanitizers under the Covalon brand name. The company sells its products through third-party distribution networks and company's direct sales force. It serves hospitals, wound care centers, burn centers, extended/alternate care and acute care facilities, home health care agencies, and physicians' offices. The company is headquartered in Mississauga, Canada.

Web site: http://www.covalon.com

Last updated September 13, 2021


Market Data powered by QuoteMedia. Terms of Use